Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

By K. Mrózek, Guido Marcucci, P. Paschka, S. Whitman, C. Bloomfield. Blood, 2007

598 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. (2010, background): “When considered together, the frequency of mutations in genes encoding the isocitrate dehydrogenases is relatively high in CN-AML (33%), placing them among the most frequent mutations in CN-AML.”
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells (2009, background): “This specimen harbored the FLT3-ITD mutation, which was detected in the bulk leukemia cells (Figure 2D).”
Stem cell gene expression programs influence clinical outcome in human leukemia (2011, background): “Cytogenetically normal AML represents ∼45% of all AML cases and identifies a subject population of intermediate ris”